Related Experiment Video
Updated: Feb 11, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
[Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review]
Xin Cheng1, Ya-Jie Wang2, Shuai Feng1
1Medical College of Kunming University of Science and Technology, Kunming 650000, Yunnan Province, China; Department of Hemato- logy, The First People's Hospital Affiliated to Kunming University of Science and Technology,Kunming 650000, Yunnan Province, China.
Abstract:
The chimeric antigen receptor (CAR) T cell therapy has gradually became a new trend in the treatment of refractory and relapsed hematologic malignancies by developing for 30 years. With the exciting development of genetic engineering, CAR-T technology has subjected to 4 generations of innovation. Structure of CAR-T started from a single signal molecule to 2 or more than 2 co-stimulatory molecules, and then coding the CAR gene or promoter. CAR-T can specifically recognize tumor antigens, and does not be restricted by major histocompatibility complex (MHC), thus making a breakthrough in clinical treatment. In this review, the history, structure and mechanism of action of CAR-T, as well as the current status and challenges of CAR-T immunotherapy in acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma are summarized.
Related Concept Videos
Tumor Immunotherapy
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Marcia's Theory of Identity Status
Electrical Current
Current Density

